Mary E.D. Flowers

46.9k total citations · 7 hit papers
339 papers, 20.0k citations indexed

About

Mary E.D. Flowers is a scholar working on Hematology, Oncology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Mary E.D. Flowers has authored 339 papers receiving a total of 20.0k indexed citations (citations by other indexed papers that have themselves been cited), including 250 papers in Hematology, 89 papers in Oncology and 80 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Mary E.D. Flowers's work include Hematopoietic Stem Cell Transplantation (226 papers), Acute Lymphoblastic Leukemia research (70 papers) and Childhood Cancer Survivors' Quality of Life (52 papers). Mary E.D. Flowers is often cited by papers focused on Hematopoietic Stem Cell Transplantation (226 papers), Acute Lymphoblastic Leukemia research (70 papers) and Childhood Cancer Survivors' Quality of Life (52 papers). Mary E.D. Flowers collaborates with scholars based in United States, South Africa and Brazil. Mary E.D. Flowers's co-authors include Paul J. Martin, Stephanie J. Lee, Rainer Storb, Barry E. Storer, Frederick R. Appelbaum, H. Joachim Deeg, Georgia B. Vogelsang, Paul A. Carpenter, Wendy M. Leisenring and Brenda M. Sandmaier and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Mary E.D. Flowers

331 papers receiving 19.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers

2001 700 citations Paul J. Martin, Barry E. Storer et al. profile →
Chronic graft-versus-host disease

2003 697 citations Stephanie J. Lee, Mary E.D. Flowers et al. Biology of Blood and Marrow Transplantation profile →
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.

1991 626 citations F R Appelbaum, Mary E.D. Flowers et al. profile →
Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria

2011 453 citations Mary E.D. Flowers, Yoshihiro Inamoto et al. Blood profile →
Cord-Blood Transplantation in Patients with Minimal Residual Disease

2016 284 citations Filippo Milano, Ted Gooley et al. profile →
Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report

2015 280 citations Stephanie J. Lee, Yoshihiro Inamoto et al. Biology of Blood and Marrow Transplantation profile →
EBMT−NIH−CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment

2018 266 citations Stephanie J. Lee, Mary E.D. Flowers et al. Bone Marrow Transplantation profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mary E.D. Flowers United States	77	14.2k	5.4k	4.8k	3.9k	3.1k	339	20.0k
Brenda M. Sandmaier United States	74	16.1k 1.1×	5.1k 0.9×	5.4k 1.1×	4.8k 1.2×	3.5k 1.1×	421	21.8k
Ted Gooley United States	73	10.3k 0.7×	4.7k 0.9×	4.9k 1.0×	3.0k 0.8×	2.2k 0.7×	322	18.3k
Aloïs Gratwohl Switzerland	80	17.1k 1.2×	5.7k 1.1×	4.7k 1.0×	4.4k 1.1×	4.8k 1.5×	515	23.8k
Jakob Passweg Switzerland	72	13.3k 0.9×	4.7k 0.9×	6.1k 1.3×	2.7k 0.7×	5.5k 1.8×	497	21.0k
Mohamad Mohty France	82	18.6k 1.3×	6.4k 1.2×	7.6k 1.6×	5.9k 1.5×	3.4k 1.1×	928	26.0k
Keith M. Sullivan United States	66	11.0k 0.8×	4.6k 0.8×	3.9k 0.8×	2.7k 0.7×	3.0k 1.0×	241	16.5k
Robert J. Soiffer United States	89	15.0k 1.1×	10.6k 2.0×	7.1k 1.5×	3.3k 0.8×	3.7k 1.2×	506	25.4k
Gèrard Socié France	91	18.7k 1.3×	9.2k 1.7×	7.4k 1.5×	4.9k 1.3×	4.8k 1.6×	701	30.2k
Corey Cutler United States	73	13.1k 0.9×	6.8k 1.3×	4.0k 0.8×	3.1k 0.8×	3.2k 1.0×	449	18.2k
Donna Przepiorka United States	59	12.0k 0.8×	5.6k 1.0×	5.5k 1.1×	2.6k 0.7×	3.0k 1.0×	197	18.2k

Countries citing papers authored by Mary E.D. Flowers

Since Specialization

Citations

This map shows the geographic impact of Mary E.D. Flowers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E.D. Flowers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E.D. Flowers more than expected).

Fields of papers citing papers by Mary E.D. Flowers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E.D. Flowers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E.D. Flowers. The network helps show where Mary E.D. Flowers may publish in the future.

Co-authorship network of co-authors of Mary E.D. Flowers

This figure shows the co-authorship network connecting the top 25 collaborators of Mary E.D. Flowers. A scholar is included among the top collaborators of Mary E.D. Flowers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary E.D. Flowers. Mary E.D. Flowers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baumrin, Emily, Michael Byrne, Paul J. Martin, et al.. (2023). Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease. JAMA Dermatology. 159(4). 393–393. 7 indexed citations

Okamoto, Shinichiro, Minako Iida, Nada Hamad, et al.. (2023). American Society of Transplantation and Cellular Therapy International Affair Committee: Report of the Third Workshop on Global Perspective to Access to Transplantation at the 2022 Tandem Meeting. Transplantation and Cellular Therapy. 29(7). 410–417. 2 indexed citations

Morsink, Linde M., Megan Othus, Filippo Milano, et al.. (2022). Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 139(11). 1694–1706. 47 indexed citations

Ullrich, Christina, Kelsey K. Baker, Paul A. Carpenter, et al.. (2022). Fatigue in Hematopoietic Cell Transplantation Survivors: Correlates, Care Team Communication, and Patient-Identified Mitigation Strategies. Transplantation and Cellular Therapy. 29(3). 200.e1–200.e8. 8 indexed citations

Onstad, Lynn, et al.. (2021). Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. Bone Marrow Transplantation. 57(1). 83–88. 2 indexed citations

Cushing‐Haugen, Kara L., Michael Boeckh, Paul A. Carpenter, et al.. (2020). Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. Blood Advances. 4(7). 1232–1241. 15 indexed citations

Duke, Elizabeth R., Brian D. Williamson, Bhavesh Borate, et al.. (2020). CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation. 131(1). 40 indexed citations

Kornblit, Brian, Barry E. Storer, Niels Smedegaard Andersen, et al.. (2020). Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors. Blood. 136(13). 1499–1506. 14 indexed citations

Puronen, Camille E., Ryan D. Cassaday, Philip A. Stevenson, et al.. (2018). Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation. 24(11). 2211–2215. 8 indexed citations

10.

Inamoto, Yoshihiro, Paul J. Martin, Mary E.D. Flowers, et al.. (2016). Genetic risk factors for sclerotic graft-versus-host disease. Blood. 128(11). 1516–1524. 9 indexed citations

11.

Yu, Jeffrey, Barry E. Storer, Kushi Kushekhar, et al.. (2016). Biomarker Panel for Chronic Graft-Versus-Host Disease. Journal of Clinical Oncology. 34(22). 2583–2590. 89 indexed citations

12.

Mielcarek, Marco, T Furlong, Barry E. Storer, et al.. (2015). Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica. 100(6). 842–848. 60 indexed citations

13.

Yeung, Cecilia C.S., Aaron T. Gerds, Min Fang, et al.. (2015). Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing. Biology of Blood and Marrow Transplantation. 21(9). 1565–1575. 16 indexed citations

14.

Inamoto, Yoshihiro, Mary E.D. Flowers, Brenda M. Sandmaier, et al.. (2014). Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 124(8). 1363–1371. 86 indexed citations

15.

Flowers, Mary E.D., Yoshihiro Inamoto, Paul A. Carpenter, et al.. (2011). Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 117(11). 3214–3219. 453 indexed citations breakdown →

16.

Lee, Stephanie J. & Mary E.D. Flowers. (2008). Recognizing and Managing Chronic Graft-Versus-Host Disease. Hematology. 2008(1). 134–141. 184 indexed citations

17.

Flowers, Mary E.D., Barry E. Storer, Paul A. Carpenter, et al.. (2008). Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. 14(12). 1380–1384. 44 indexed citations

18.

Leisenring, Wendy M., Debra L. Friedman, Mary E.D. Flowers, Jeffrey L. Schwartz, & H. Joachim Deeg. (2006). Nonmelanoma Skin and Mucosal Cancers After Hematopoietic Cell Transplantation. Journal of Clinical Oncology. 24(7). 1119–1126. 117 indexed citations

19.

Flowers, Mary E.D., Carlos Roberto de Medeiros, Marco A. Bitencourt, et al.. (2005). Low‐dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA‐matched related donors in patients with Fanconi anaemia. British Journal of Haematology. 130(1). 99–106. 33 indexed citations

20.

Taiwo, Babafemi, et al.. (1992). Reducing children's fear when undergoing painful procedures.. Emergency Medicine Journal. 9(3). 306–309. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact